EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Pulmonary Arterial Hypertension - Pipeline Review, H1 2017

  • ID: 4091089
  • Report
  • March 2017
  • 227 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Actelion Ltd
  • Camurus AB
  • Galectin Therapeutics Inc
  • Liquidia Technologies Inc
  • Nippon Kayaku Co Ltd
  • Proteo Inc
  • MORE
Pulmonary Arterial Hypertension - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Pulmonary Arterial Hypertension - Pipeline Review, H1 2017, provides an overview of the Pulmonary Arterial Hypertension (Cardiovascular) pipeline landscape.

Pulmonary arterial hypertension (PAH) is a type of high blood pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. Symptoms include chest pain, fatigue, passing out suddenly, and swelling of the legs (edema). Risk factors include family history, age, obesity, obstructive sleep apnea and other diseases, including congenital heart disease, lung disease, liver disease and connective tissue disorders like scleroderma and lupus. Treatment includes sildenafil, prostanoids and calcium channel blockers.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Pulmonary Arterial Hypertension - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Pulmonary Arterial Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 7, 9, 11, 36, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pulmonary Arterial Hypertension (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pulmonary Arterial Hypertension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular).
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pulmonary Arterial Hypertension (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Actelion Ltd
  • Camurus AB
  • Galectin Therapeutics Inc
  • Liquidia Technologies Inc
  • Nippon Kayaku Co Ltd
  • Proteo Inc
  • MORE
Introduction

Pulmonary Arterial Hypertension - Overview

Pulmonary Arterial Hypertension - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Pulmonary Arterial Hypertension - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Pulmonary Arterial Hypertension - Companies Involved in Therapeutics Development

Actelion Ltd

APT Therapeutics Inc

Arena Pharmaceuticals Inc

Ascendis Pharma A/S

Asklepion Pharmaceuticals LLC

AVEO Pharmaceuticals Inc

Bial - Portela & Ca SA

Camurus AB

Celsion Corp

Celtaxsys Inc

Chiesi Farmaceutici SpA

Eli Lilly and Company

F. Hoffmann-La Roche Ltd

Galectin Therapeutics Inc

HitGen LTD

Insmed Inc

INSYS Therapeutics Inc

INVENT Pharmaceuticals Inc

Johnson & Johnson

Kowa Company Ltd

Liquidia Technologies Inc

MannKind Corp

Mast Therapeutics Inc

Mezzion Pharma Co Ltd

miRagen Therapeutics Inc

Morphogen-IX Ltd

Nippon Kayaku Co Ltd

Nippon Shinyaku Co Ltd

Northern Therapeutics Inc

Novartis AG

Peloton Therapeutics Inc

PhaseBio Pharmaceuticals Inc

Pluristem Therapeutics Inc

Polyphor Ltd

Proteo Inc

Pulmokine Inc

Reata Pharmaceuticals Inc

Respira Therapeutics Inc

Reviva Pharmaceuticals Inc

Selten Pharma Inc

Serodus ASA

Silence Therapeutics Plc

SteadyMed Therapeutics Inc

Suda Ltd

Toray Industries Inc

United Therapeutics Corp

Vivus Inc

Pulmonary Arterial Hypertension - Drug Profiles

(macitentan + tadalafil) - Drug Profile

acebilustat - Drug Profile

Antibody to Inhibit TRAIL for Pulmonary Arterial Hypertension - Drug Profile

Antisense Oligonucleotide to Inhibit miR-145 for Pulmonary Arterial Hypertension - Drug Profile

APT-602 - Drug Profile

ascomycin - Drug Profile

AV-353 - Drug Profile

bardoxolone methyl - Drug Profile

beraprost sodium SR - Drug Profile

BIA-51058 - Drug Profile

BMP-10 - Drug Profile

BMP-9 - Drug Profile

Cell Therapy to Activate eNOS for Pulmonary Arterial Hypertension - Drug Profile

CTX-3397 - Drug Profile

Drugs to Inhibit Notch3 for Pulmonary Arterial Hypertension - Drug Profile

esuberaprost sodium MR + treprostinil - Drug Profile

GMA-301 - Drug Profile

GMCT-01 - Drug Profile

GRMD-02 - Drug Profile

INS-1009 - Drug Profile

INV-240 - Drug Profile

JNJ-26993135 - Drug Profile

KAR-5585 - Drug Profile

L-Citrulline - Drug Profile

macitentan - Drug Profile

MD-0701 - Drug Profile

MFC-1040 - Drug Profile

MFC-2040 - Drug Profile

NK-104 NP - Drug Profile

Oligonucleotide to Inhibit Endothelin-1 for Lung Cancer, Pulmonary Arterial Hypertension and Respiratory Disorders - Drug Profile

Oligonucleotide to Inhibit MicroRNA-145 for Pulmonary Arterial Hypertension - Drug Profile

PB-1046 - Drug Profile

PB-1120 - Drug Profile

PF-543 - Drug Profile

PK-10453 - Drug Profile

PK-10571 - Drug Profile

PLX-PAD - Drug Profile

POL-6014 - Drug Profile

PT-2977 - Drug Profile

QCC-374 - Drug Profile

R-190 - Drug Profile

ralinepag - Drug Profile

RP-5063 - Drug Profile

RT-234 - Drug Profile

selexipag - Drug Profile

SER-100 - Drug Profile

sildenafil citrate - Drug Profile

sirolimus - Drug Profile

sirolimus albumin-bound - Drug Profile

Small Molecule to Inhibit ROCK-2 for Cardiovascular, Ophthalmology and Oncology - Drug Profile

Small Molecules for Pulmonary Arterial Hypertension - Drug Profile

Small Molecules to Activate ACE2 for Pulmonary Arterial Hypertension - Drug Profile

Small Molecules to Antagonize 5-HT1B for Pulmonary Arterial Hypertension - Drug Profile

Small Molecules to Antagonize PDGFR for Pulmonary Arterial Hypertension - Drug Profile

Small Molecules to Inhibit Soluble Epoxide Hydrolase for Pulmonary Arterial Hypertension - Drug Profile

sodium nitrite - Drug Profile

SPI-054 - Drug Profile

SPI-183 - Drug Profile

SUD-004 - Drug Profile

Synthetic Peptide to Antagonize Urotensin-II Receptor for Pulmonary Arterial Hypertension - Drug Profile

tacrolimus - Drug Profile

tadalafil - Drug Profile

tiprelestat - Drug Profile

tocilizumab - Drug Profile

TPN-729 - Drug Profile

TR-422 - Drug Profile

treprostinil diolamine - Drug Profile

treprostinil diolamine - Drug Profile

treprostinil diolamine - Drug Profile

treprostinil diolamine - Drug Profile

treprostinil diolamine SR - Drug Profile

ubenimex - Drug Profile

udenafil - Drug Profile

VPD-380 - Drug Profile

Pulmonary Arterial Hypertension - Dormant Projects

Pulmonary Arterial Hypertension - Discontinued Products

Pulmonary Arterial Hypertension - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Pulmonary Arterial Hypertension, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Companies, H1 2017 (Contd..1), H1

Number of Products under Development by Companies, H1 2017 (Contd..2), H1

Number of Products under Development by Universities/Institutes, H1

Products under Development by Companies, H1

Products under Development by Companies, H1 2017 (Contd..1), H1

Products under Development by Companies, H1 2017 (Contd..2), H1

Products under Development by Companies, H1 2017 (Contd..3), H1

Products under Development by Universities/Institutes, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Target, H1 2017 (Contd..1), H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Pulmonary Arterial Hypertension - Pipeline by Actelion Ltd, H1

Pulmonary Arterial Hypertension - Pipeline by APT Therapeutics Inc, H1

Pulmonary Arterial Hypertension - Pipeline by Arena Pharmaceuticals Inc, H1

Pulmonary Arterial Hypertension - Pipeline by Ascendis Pharma A/S, H1

Pulmonary Arterial Hypertension - Pipeline by Asklepion Pharmaceuticals LLC, H1

Pulmonary Arterial Hypertension - Pipeline by AVEO Pharmaceuticals Inc, H1

Pulmonary Arterial Hypertension - Pipeline by Bial - Portela & Ca SA, H1

Pulmonary Arterial Hypertension - Pipeline by Camurus AB, H1

Pulmonary Arterial Hypertension - Pipeline by Celsion Corp, H1

Pulmonary Arterial Hypertension - Pipeline by Celtaxsys Inc, H1

Pulmonary Arterial Hypertension - Pipeline by Chiesi Farmaceutici SpA, H1

Pulmonary Arterial Hypertension - Pipeline by Eli Lilly and Company, H1

Pulmonary Arterial Hypertension - Pipeline by F. Hoffmann-La Roche Ltd, H1

Pulmonary Arterial Hypertension - Pipeline by Galectin Therapeutics Inc, H1

Pulmonary Arterial Hypertension - Pipeline by HitGen LTD, H1

Pulmonary Arterial Hypertension - Pipeline by Insmed Inc, H1

Pulmonary Arterial Hypertension - Pipeline by INSYS Therapeutics Inc, H1

Pulmonary Arterial Hypertension - Pipeline by INVENT Pharmaceuticals Inc, H1

Pulmonary Arterial Hypertension - Pipeline by Johnson & Johnson, H1

Pulmonary Arterial Hypertension - Pipeline by Kowa Company Ltd, H1

Pulmonary Arterial Hypertension - Pipeline by Liquidia Technologies Inc, H1

Pulmonary Arterial Hypertension - Pipeline by MannKind Corp, H1

Pulmonary Arterial Hypertension - Pipeline by Mast Therapeutics Inc, H1

Pulmonary Arterial Hypertension - Pipeline by Mezzion Pharma Co Ltd, H1

Pulmonary Arterial Hypertension - Pipeline by miRagen Therapeutics Inc, H1

Pulmonary Arterial Hypertension - Pipeline by Morphogen-IX Ltd, H1

Pulmonary Arterial Hypertension - Pipeline by Nippon Kayaku Co Ltd, H1

Pulmonary Arterial Hypertension - Pipeline by Nippon Shinyaku Co Ltd, H1

Pulmonary Arterial Hypertension - Pipeline by Northern Therapeutics Inc, H1

Pulmonary Arterial Hypertension - Pipeline by Novartis AG, H1

Pulmonary Arterial Hypertension - Pipeline by Peloton Therapeutics Inc, H1

Pulmonary Arterial Hypertension - Pipeline by PhaseBio Pharmaceuticals Inc, H1

Pulmonary Arterial Hypertension - Pipeline by Pluristem Therapeutics Inc, H1

Pulmonary Arterial Hypertension - Pipeline by Polyphor Ltd, H1

Pulmonary Arterial Hypertension - Pipeline by Proteo Inc, H1

Pulmonary Arterial Hypertension - Pipeline by Pulmokine Inc, H1

Pulmonary Arterial Hypertension - Pipeline by Reata Pharmaceuticals Inc, H1

Pulmonary Arterial Hypertension - Pipeline by Respira Therapeutics Inc, H1

Pulmonary Arterial Hypertension - Pipeline by Reviva Pharmaceuticals Inc, H1

Pulmonary Arterial Hypertension - Pipeline by Selten Pharma Inc, H1

Pulmonary Arterial Hypertension - Pipeline by Serodus ASA, H1

Pulmonary Arterial Hypertension - Pipeline by Silence Therapeutics Plc, H1

Pulmonary Arterial Hypertension - Pipeline by SteadyMed Therapeutics Inc, H1

Pulmonary Arterial Hypertension - Pipeline by Suda Ltd, H1

Pulmonary Arterial Hypertension - Pipeline by Toray Industries Inc, H1

Pulmonary Arterial Hypertension - Pipeline by United Therapeutics Corp, H1

Pulmonary Arterial Hypertension - Pipeline by Vivus Inc, H1

Pulmonary Arterial Hypertension - Dormant Projects, H1

Pulmonary Arterial Hypertension - Dormant Projects, H1 2017 (Contd..1), H1

Pulmonary Arterial Hypertension - Discontinued Products, H1

List of Figures:

Number of Products under Development for Pulmonary Arterial Hypertension, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Universities/Institutes, H1

Number of Products by Top 10 Targets, H1

Number of Products by Stage and Top 10 Targets, H1

Number of Products by Top 10 Mechanism of Actions, H1

Number of Products by Stage and Top 10 Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Top 10 Molecule Types, H1

Number of Products by Stage and Top 10 Molecule Types, H
Note: Product cover images may vary from those shown
3 of 4
  • Actelion Ltd
  • APT Therapeutics Inc
  • Arena Pharmaceuticals Inc
  • Ascendis Pharma A/S
  • Asklepion Pharmaceuticals LLC
  • AVEO Pharmaceuticals Inc
  • Bial - Portela & Ca SA
  • Camurus AB
  • Celsion Corp
  • Celtaxsys Inc
  • Chiesi Farmaceutici SpA
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Galectin Therapeutics Inc
  • HitGen LTD
  • Insmed Inc
  • INSYS Therapeutics Inc
  • INVENT Pharmaceuticals Inc
  • Johnson & Johnson
  • Kowa Company Ltd
  • Liquidia Technologies Inc
  • MannKind Corp
  • Mast Therapeutics Inc
  • Mezzion Pharma Co Ltd
  • miRagen Therapeutics Inc
  • Morphogen-IX Ltd
  • Nippon Kayaku Co Ltd
  • Nippon Shinyaku Co Ltd
  • Northern Therapeutics Inc
  • Novartis AG
  • Peloton Therapeutics Inc
  • PhaseBio Pharmaceuticals Inc
  • Pluristem Therapeutics Inc
  • Polyphor Ltd
  • Proteo Inc
  • Pulmokine Inc
  • Reata Pharmaceuticals Inc
  • Respira Therapeutics Inc
  • Reviva Pharmaceuticals Inc
  • Selten Pharma Inc
  • Serodus ASA
  • Silence Therapeutics Plc
  • SteadyMed Therapeutics Inc
  • Suda Ltd
  • Toray Industries Inc
  • United Therapeutics Corp
  • Vivus Inc
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll